XVIVO Perfusion AB's share warrant program 2015/2017 is fully subscribed. A total of 215,000 warrants with the right to subscribe for new shares were issued. Each warrant has in June 2017 the right to subscribe for one new share at a price of SEK 60.92.
The annual shareholder meeting April 23, 2015 approved the warrant program of a maximum of 215,000 warrants to be offered to all employees in XVIVO Perfusion AB. Upon full exercise of the warrants, the share capital increase is SEK 5,500 corresponding to a dilution of about 1 percent of the total number of shares and votes.
Magnus Nilsson, CEO of XVIVO Perfusion: “The broad support is very encouraging and it gives all of our employees a stronger shareholder interest and an even stronger incentive to fulfill our goals.”
July 2, 2015
Gothenburg
XVIVO Perfusion AB (publ)